Navigation Links
CeNeRx Initiates Phase II Trial of TriRima™ as Monotherapy in Treatment Resistant Depression
Date:1/6/2011

in treatment resistant depression, and we are delighted that our Phase II trial is now enrolling patients," said Daniel Burch, MD, Chief Medical Officer of CeNeRx.  "The new formulation of TriRima has demonstrated excellent safety in multiple studies to date, and we believe that it has the potential to become the first agent to achieve the triple action efficacy of MAO inhibitor drugs without their limiting side effects."

The modified release formulation of TriRima has major advantages over the version used in earlier studies.  In addition to displaying excellent pharmacokinetic properties, the dosing frequency has been reduced to one tablet administered once or twice daily.

"TriRima addresses a large unmet medical need -- currently a substantial proportion of patients with major depression do not receive adequate relief from their therapy," noted Barry Brand, Chief Executive Officer of CeNeRx.  "TriRima has the potential to be the first option that provides these patients superior efficacy and a good safety profile as monotherapy, and we look forward to advancing the Phase II trial in the coming year."

CeNeRx will be presenting at the Biotech Showcase 2011 meeting at 11:00 AM PST on January 11.  The conference is being held January 10-12, 2011 at the Parc 55 Wyndham, San Francisco.   More information on the meeting can be found at www.ebdgroup.com/bts/index.php.

.

About CeNeRx BioPharmaCeNeRx is a privately held clinical-stage biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system.  CeNeRx's most advanced compound, a reversible inhibitor of monoamine oxidase, or RIMA, is in Phase II development for treatment resistant depression.  RIMAs may have efficacy advantages over current agents for depression and are expected to have a good safety profil
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
2. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
3. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
4. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
5. CeNeRx BioPharma Completes $13 Million Series C Financing
6. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
9. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
10. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
11. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015 Zimmer Holdings, Inc. ... today announced that its Board of Directors has approved the ... second quarter of 2015. The cash dividend of ... 14, 2015, to stockholders of record as of the close ... are subject to approval of the Board of Directors and ...
(Date:5/5/2015)... Silver Creek Pharmaceuticals, Inc. announced today the ... from the National Institute of Health (NIH). ... based biotechnology company that discovers and develops ... disease. This award will be used to advance their ... a heart attack. Silver Creek,s Smart Growth ...
(Date:5/5/2015)... 2015  Trovagene, Inc. (NASDAQ:  TROV), a developer ... results for the three months ended March 31, ... we presented favorable clinical results at ASCO GI, ... our Precision Cancer Monitoring platform,s ability to detect ... lung cancers," said Antonius Schuh, Ph.D., chief executive ...
Breaking Medicine Technology:Silver Creek Pharmaceuticals Awarded NIH SBIR Grant for Smart Growth Factor Technology 2Trovagene, Inc. Announces First Quarter 2015 Financial Results 2Trovagene, Inc. Announces First Quarter 2015 Financial Results 3Trovagene, Inc. Announces First Quarter 2015 Financial Results 4Trovagene, Inc. Announces First Quarter 2015 Financial Results 5Trovagene, Inc. Announces First Quarter 2015 Financial Results 6
... MORGANTOWN, W.Va., Jan. 11, 2011 A Blanchette ... the Journal of Neuroscience reveals underlying causes for ... identifies promising pharmaceutical solutions for the devastating condition ... the United States. The BRNI study is the ...
... Jan. 11, 2011 Hill-Rom Holdings, Inc. (NYSE: ... on Wednesday, January 26, 2011.  The company will host a ... 8 a.m. EST. Earnings Release:   Hill-Rom,s ... December 31, 2010, will be issued to the public after ...
Cached Medicine Technology:The Blanchette Rockefeller Neurosciences Institute Identifies Groundbreaking New Therapies for Prevention and Treatment of Alzheimer's Disease 2The Blanchette Rockefeller Neurosciences Institute Identifies Groundbreaking New Therapies for Prevention and Treatment of Alzheimer's Disease 3Hill-Rom Holdings, Inc. Hosts Fiscal 2011 First Quarter Earnings Webcast 2
(Date:5/6/2015)... In celebration of their twentieth anniversary, ... they will give away a deluxe human hair lace wig ... steps to enter on a third-party giveaway tool. The important ... can be the winner. , The hair is a crown, ... destination for such a jewel for the past 20 years. ...
(Date:5/6/2015)... 06, 2015 Qualidigm , ... has hired healthcare executive Ann Olson, RN, BSN, ... will lead Qualidigm’s growing home healthcare services and ... improve the quality, safety, and cost-effectiveness of healthcare ... from Interim HealthCare of North Haven, Inc., a ...
(Date:5/6/2015)... Pass, OR (PRWEB) May 06, 2015 ... for maintaining eye health as we age, is fully ... the Sharon Kleyne Hour™ Power of Water® radio show. ... the need to drink sufficient water each day. As ... Nature’s Tears® EyeMist® for dry eye, Kleyne has extensive ...
(Date:5/6/2015)... 2015 Chinese technology company, Elink-IOT, has ... to raise AUD$150,000 to finalize development of Watcher, the ... smart watch designed to help the owner keep track ... when the item is out of range. , ... the wearer and sends alerts on its E-paper display, ...
(Date:5/6/2015)... LINET Americas has been awarded the ... small business category. The award was given for outstanding ... is given on an annual basis to foreign owned ... to philanthropy. Since 1998, the Charlotte International Cabinet ... Mayor’s International Community Awards. The award was presented to ...
Breaking Medicine News(10 mins):Health News:PremierLaceWigs.com Human Hair Lace Wigs Giveaway Could Change Your Hairstyle 2Health News:Innovative Healthcare Executive Ann Olson Joins Qualidigm as Principal and Vice President 2Health News:Innovative Healthcare Executive Ann Olson Joins Qualidigm as Principal and Vice President 3Health News:National Eye Institute’s Eye Care as You Age report endorsed by fresh water advocate Sharon Kleyne – with one addition 2Health News:National Eye Institute’s Eye Care as You Age report endorsed by fresh water advocate Sharon Kleyne – with one addition 3Health News:Crowdfunding campaign Launched for World’s First Anti-Loss Smart Watch 2Health News:LINET Americas Wins The Mayor's International Community Award in Charlotte 2
... Dec. 10 N3 Oceanic, Inc. announced the addition of ... developed by cardiologist Dr. Jeffrey Shapiro, MD, Assistant Professor of ... and NYU Langone Medical Center, who has been giving the ... life-changing results. Dr. Shapiro states, Orosine is the most significant ...
... Global Med Technologies(R), Inc.,("Global Med" or the "Company") ... technology company, today announced that due to,inquiries from ... that was,received from Victory Park Capital Advisors, LLC ... Global Med,s Board of Directors to investigate various,business ...
... Botanical Council (ABC) has officially launched its Adopt-an-Herb program, ... ( Camellia sinensis ). For the next three years, ... ensure that abstracts (summaries) of the latest published scientific ... ABC,s HerbMedPro database, one of the most robust and ...
... Dec. 10 Genomma Lab Internacional,S.A.B. de C.V. (BMV: ... ("OTC") pharmaceuticals and personal care products company,announced today its ... growth without considering acquisitions in the range of 21% ... the range of 27% - 28%. These estimates,are ...
... stress of the economy,have you pulling your hair out? ... Now is the time to take a breather, rejuvenate, ... emotionally,physically and financially, which is why many spas are offering ... get the other half off,there is something for everyone. ...
... Dec. 10 Napo Pharmaceuticals, Inc. ("Napo"),is pleased ... for the license of crofelemer for all indications ... Japan, and certain,indications worldwide. Crofelemer is Napo,s ... 3 trial for the treatment of,chronic diarrhea in ...
Cached Medicine News:Health News:Res-Q Gains Rights To Market Orosine - a Breakthrough, Patented, Natural Heart Supplement That Cardiologists Are Calling the 'Ultimate Cardio Protection' Against Heart Attacks, Strokes and Heart Failure. 2Health News:Global Med Technologies(R), Inc. Clarifies Proposal Received from Victory Park Capital Advisors, LLC 2Health News:Tea Dragon Films is First Adopter in the American Botanical Council's New Adopt-An-Herb Program 2Health News:Tea Dragon Films is First Adopter in the American Botanical Council's New Adopt-An-Herb Program 3Health News:Tea Dragon Films is First Adopter in the American Botanical Council's New Adopt-An-Herb Program 4Health News:Genomma Lab Announces 2009 Earnings Guidance 2Health News:Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals 2Health News:Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals 3Health News:Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals 4Health News:Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals 5
The Midas II Stainer is an automated slide stainer designed for use in hematology and microbiology laboratories....
... an "assembly-line worker" for routine staining protocols ... Programmable continuous slide stainer for routine stains. ... in short time. Its large number of ... working principle provides a high throughput. A ...
Cholesterol, Total. An automated analyzer test kits....
Intended for the quantitative determination of total cholesterol in serum. Reaction: Endpoint. Reaction complete within five minutes. Wavelength: 500 nm. Linearity: 700 mg/dL (18.1 mmol/L). Single st...
Medicine Products: